Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.
Nina Shah, MD: One of the biggest breakthroughs that we've had for multiple myeloma is the first FDA-approved engineered T-cell therapy. It happened midway through the year in the spring, giving us the approval for the bb2121 product, also known as ide-cel [idecabtagene vicleucel; Abecma], for patients with relapsed or refractory multiple myeloma [after 4 or more prior lines of therapy]. That's probably the biggest breakthrough but we've also had some interesting other breakthroughs, which include approvals of certain forms of daratumumab (Darzalex), for example, the subcutaneous form, in conjunction with carfilzomib (Kyprolis) and dexamethasone for relapsed or refractory disease in [patients who received] 1 to 3 prior lines [of therapy]. Similarly, isatuximab (Sarclisa), carfilzomib, and dexamethasone has also been approved. We have a lot more options for our patients in the relapsed or refractory setting.
